FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280628550> ?p ?o ?g. }

• W4280628550 endingPage "23" @default.
• W4280628550 startingPage "16" @default.
• W4280628550 abstract "Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for patients with CRPC remains unclear.To evaluate whether ENZ or ABI is better as first-line treatment for CRPC.An investigator-initiated, multicenter, randomized controlled trial was conducted in Japan. The study enrolled 203 patients with CRPC before chemotherapy between February 20, 2015, and July 31, 2019. Patients were randomly assigned 1:1 to the ENZ or ABI arm.The primary endpoint was time to prostate-specific antigen (PSA) progression. Secondary endpoints included the PSA response rate (≥50% decline from baseline), overall survival, and safety. A log-rank test was used for comparison of survival analyses between arms.After randomization, 92 patients in each arm were treated and analyzed. Time to PSA progression did not significantly differ between the arms (median 21.2 mo for ENZ and 11.9 mo for ABI; hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.51-1.27; p = 0.1732). There was a significant difference in the PSA response rate between the arms (72% for ENZ and 57% for ABI; p = 0.0425). There was no significant difference in overall survival (median 32.9 mo for ENZA and 35.5 mo for ABI; HR 1.17, 95% CI 0.72-1.88; p = 0.5290). Grade ≥3 adverse events were observed in 11% of patients in the ENZA arm and 21% in the ABI arm (p = 0.1044).ENZ did not show any survival benefit in comparison to ABI, but showed a better PSA response rate with a low rate of severe adverse events in CRPC.Results from our study suggest that use of enzalutamide before abiraterone may have potential clinical benefits for patients with castration-resistant prostate cancer." @default.
• W4280628550 created "2022-05-22" @default.
• W4280628550 creator A5010599130 @default.
• W4280628550 creator A5024405031 @default.
• W4280628550 creator A5034815662 @default.
• W4280628550 creator A5036460015 @default.
• W4280628550 creator A5039868774 @default.
• W4280628550 creator A5042020714 @default.
• W4280628550 creator A5044574879 @default.
• W4280628550 creator A5051605638 @default.
• W4280628550 creator A5056369807 @default.
• W4280628550 creator A5059843860 @default.
• W4280628550 creator A5069662118 @default.
• W4280628550 creator A5070315642 @default.
• W4280628550 creator A5071529858 @default.
• W4280628550 creator A5077496785 @default.
• W4280628550 creator A5081014415 @default.
• W4280628550 creator A5081630823 @default.
• W4280628550 creator A5085013416 @default.
• W4280628550 creator A5085521043 @default.
• W4280628550 creator A5086487041 @default.
• W4280628550 date "2022-07-01" @default.
• W4280628550 modified "2023-09-27" @default.
• W4280628550 title "Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial" @default.
• W4280628550 cites W115308025 @default.
• W4280628550 cites W2002941893 @default.
• W4280628550 cites W2018291607 @default.
• W4280628550 cites W2032649515 @default.
• W4280628550 cites W2055346449 @default.
• W4280628550 cites W2086007073 @default.
• W4280628550 cites W2101496134 @default.
• W4280628550 cites W2110534364 @default.
• W4280628550 cites W2137467802 @default.
• W4280628550 cites W2148643283 @default.
• W4280628550 cites W2165782799 @default.
• W4280628550 cites W2166918329 @default.
• W4280628550 cites W2167331614 @default.
• W4280628550 cites W2235523093 @default.
• W4280628550 cites W2464502417 @default.
• W4280628550 cites W2764113329 @default.
• W4280628550 cites W2975457177 @default.
• W4280628550 cites W2984712394 @default.
• W4280628550 cites W3010077430 @default.
• W4280628550 cites W3024793319 @default.
• W4280628550 cites W3031020438 @default.
• W4280628550 cites W3119442987 @default.
• W4280628550 cites W3131822249 @default.
• W4280628550 cites W3134889720 @default.
• W4280628550 cites W3160766234 @default.
• W4280628550 cites W3181786491 @default.
• W4280628550 cites W3198679149 @default.
• W4280628550 cites W4298017640 @default.
• W4280628550 cites W585453445 @default.
• W4280628550 doi "https://doi.org/10.1016/j.euros.2022.04.016" @default.
• W4280628550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35813251" @default.
• W4280628550 hasPublicationYear "2022" @default.
• W4280628550 type Work @default.
• W4280628550 citedByCount "1" @default.
• W4280628550 countsByYear W42806285502022 @default.
• W4280628550 crossrefType "journal-article" @default.
• W4280628550 hasAuthorship W4280628550A5010599130 @default.
• W4280628550 hasAuthorship W4280628550A5024405031 @default.
• W4280628550 hasAuthorship W4280628550A5034815662 @default.
• W4280628550 hasAuthorship W4280628550A5036460015 @default.
• W4280628550 hasAuthorship W4280628550A5039868774 @default.
• W4280628550 hasAuthorship W4280628550A5042020714 @default.
• W4280628550 hasAuthorship W4280628550A5044574879 @default.
• W4280628550 hasAuthorship W4280628550A5051605638 @default.
• W4280628550 hasAuthorship W4280628550A5056369807 @default.
• W4280628550 hasAuthorship W4280628550A5059843860 @default.
• W4280628550 hasAuthorship W4280628550A5069662118 @default.
• W4280628550 hasAuthorship W4280628550A5070315642 @default.
• W4280628550 hasAuthorship W4280628550A5071529858 @default.
• W4280628550 hasAuthorship W4280628550A5077496785 @default.
• W4280628550 hasAuthorship W4280628550A5081014415 @default.
• W4280628550 hasAuthorship W4280628550A5081630823 @default.
• W4280628550 hasAuthorship W4280628550A5085013416 @default.
• W4280628550 hasAuthorship W4280628550A5085521043 @default.
• W4280628550 hasAuthorship W4280628550A5086487041 @default.
• W4280628550 hasBestOaLocation W42806285501 @default.
• W4280628550 hasConcept C121608353 @default.
• W4280628550 hasConcept C126322002 @default.
• W4280628550 hasConcept C126894567 @default.
• W4280628550 hasConcept C143998085 @default.
• W4280628550 hasConcept C168563851 @default.
• W4280628550 hasConcept C197934379 @default.
• W4280628550 hasConcept C203092338 @default.
• W4280628550 hasConcept C204243189 @default.
• W4280628550 hasConcept C207103383 @default.
• W4280628550 hasConcept C2775832370 @default.
• W4280628550 hasConcept C2776551883 @default.
• W4280628550 hasConcept C2777899217 @default.
• W4280628550 hasConcept C2780192828 @default.
• W4280628550 hasConcept C44249647 @default.
• W4280628550 hasConcept C61367390 @default.
• W4280628550 hasConcept C71924100 @default.
• W4280628550 hasConceptScore W4280628550C121608353 @default.
• W4280628550 hasConceptScore W4280628550C126322002 @default.

• next